
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. is leveraging its innovative Dynamo platform, which effectively combines computational and experimental techniques for drug discovery, focusing on precision oncology and genetic diseases. Recent clinical data indicate significant improvements in objective response rates (ORR) and progression-free survival (mPFS) among patients with kinase mutations, particularly with the RLY-2608 product candidate, which demonstrates enhanced tolerability and durability in treatment outcomes for breast cancer patients. With a robust cash position of $781 million earmarked for funding ongoing trials, Relay Therapeutics is well-positioned to advance its pipeline toward potentially impactful therapeutic developments, thus fostering a positive outlook for the company's stock.
Bears say
Relay Therapeutics Inc. is projected to face significant financial challenges, with anticipated losses of $2.15 per share in 2025, following a net loss of $2.36 per share in 2024. Key risks contributing to the negative outlook include potential negative clinical trial results, delays in development timelines, and hurdles in obtaining regulatory approvals, all of which could adversely affect the company's ability to generate revenue and secure market success. Additionally, the competitive landscape poses threats with therapies exhibiting safety limitations and the possibility of medium- to long-term dilution risks further exacerbating financial instability.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares